Vetter joins United Nations Global Compact Network
Vetter (Ravensbury, Germany), the aseptic filling and packaging CDMO has signed up to the UN Global Compact Network.
They join 308 other biopharmaceutical companies who are also a part of the agreement to work towards more sustainable business practices. Outside of the biopharmaceutical field, over 15,000 companies and 3,000 not-for-profit organisations, from 160 countries, are included in the network.
The Network is defined by ten principles, which Vetter will now have to follow as part of it’s corporate actions. The main focus of the principles is upholding human and employee rights, engaging tactics to prevent corruption, and to limit global warming.
Henryk Badack, Senior Vice President Technical Service and Internal Project Management at Vetter explained:
"We have already been pursuing a very ambitious sustainability strategy for years. By committing to the goals of the UN Global Compact, we are reaching the next level and are further expanding our initiatives to a global level."
As a collaborative network, Vetter will be able to join forces with the other companies within the agreement to work towards the same goals. The initiative means that these companies and organisations can share knowledge, ideas, and resources in the hope of upgrading processes and inciting change across the industry. Vetter will be held accountable to the goals of the compact network through a written annual report that will be open to the public, which doubles as evidence of the project and a progress report to inform the wider network.
"As a family-owned business in the healthcare sector, we bear great responsibility,” stated Badack. “And we believe in the power of cooperation. The UN Global Compact combines these two approaches very well and is also a strong commitment to shared values and goals across business sectors and national borders."
Vetter had already in place a set of it’s own sustainability values and targets, the combination will serve to better support their customers in ensuring a more sustainable supply chain and more ESG-friendly operations.
Join a global discussion at CPHI Barcelona
What does the UN Global Compact Network mean for your business – and the wider pharma industry? Join us at CPHI Barcelona and hear from expert speakers about the many, varied ways we can all work towards more sustainable practices.
Your CPHI Barcelona pass gives you access to all conference sessions, including the Creating a Circular Economy conference track, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...